RxSight Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
10.6%projected annual EPS growth
Analyst Coverage
7analysts covering
FY Revenue (est.)
$138.3Mnext fiscal year
FY EPS (est.)
-$0.70next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Light Adjustable Lens (LAL) Unit Sales Quarterly27.5K
Light Delivery Device (LDD) Unit Sales Quarterly20
LDD Cumulative Installed Base Quarterly1.2K
Gross Profit Margin Quarterly76.1%Target: 70 to 72%
Watch Items
- LDD Capital Placement PacingTrigger: LDD quarterly sales falling below 15 unitsAction: Re-evaluate commercial sales incentives and doctor onboarding programs to accelerate capital equipment adoption.
- LAL Same-Store Utilization RatesTrigger: Average monthly utilization dropping below historical baselineAction: Deploy targeted customer re-engagement programs and clinical support teams to drive surgeon confidence.
- Operating Expense ManagementTrigger: Full-year operating expenses exceeding $160 millionAction: Implement cost-containment measures across non-commercial SG&A and optimize international infrastructure spend.
Research as of 19 Jun 2026